Noninvasive imaging biomarkers to see if ophthalmic artery narrowing relates to geographic atrophy in age-related macular degeneration
Official title: Noninvasive Imaging Biomarkers of Treatable Macrovascular Disease in Age-related Macular Degeneration.
Run by The Cleveland Clinic · NCT07798323 · Data updated 2026-11-12
This study tests whether narrowed ophthalmic artery vessels are linked to the development or worsening of geographic atrophy in people with dry age-related macular degeneration.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 50 Years to 80 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | The Cleveland Clinic Academic / other |
| Locations | 1 site (Cleveland, Ohio) |
| Status | Recruiting |
| Started | September 1, 2026 |
| Main results expected | December 2028 |
| Study ends | December 2028 |
| Registry record updated | September 3, 2026 |
| Trial ID | NCT07798323 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 50-80 with asymmetric dry AMD and GA in at least one eye, treated at Cleveland Clinic, with adequate image quality.
✕Probably not a fit
Patients with bilateral symmetric GA, wet AMD, or other retinal diseases may not benefit from the findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective observational study examines the relationship between ophthalmic artery stenosis and geographic atrophy in patients with dry AMD. Eligible participants are adults aged 50-80 with asymmetric GA, treated at the Cole Eye Institute. The study will use noninvasive imaging to quantify arterial narrowing and GA progression, with exclusion criteria designed to avoid interference from other retinal diseases or poor image quality. No interventions are described; the focus is on imaging biomarkers and natural history. Results may illuminate a potential vascular contribution to GA progression and help stratify future research directions.
Why it matters
Potential benefit: If successful, the study could improve understanding of GA progression and help identify imaging markers that predict disease trajectory.
How similar studies have gone: Previous work has explored imaging biomarkers in AMD, but evidence linking ophthalmic artery narrowing to GA progression remains exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 50-80 years of age * All genders * Asymmetric dry AMD with geographic atrophy in at least one eye and reduced disease severity in the other eye according to International Classification of Disease (ICD) codes * Treated at the Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio Exclusion Criteria: * Poor image quality that limits quantification * GA extending beyond the borders of the SDOCT field of view. * Bilateral symmetric geographic atrophy. * Diagnosis of wet AMD. * Any retinal fluid at baseline. * Other concurrent retinal diseases * Vitreoretinal surgery. * Allergy to iodinated contrast agents. * Chronic kidney disease with eGFR \< 60
Where it's running
-
Cleveland Clinic
Cleveland, Ohio, United States Recruiting
Study contacts
- Study coordinator: Sara Lautzenhiser Research Coordinator
- Email: LAUTZES@ccf.org
- Phone: 216-444-3026
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Multimodal-feedback vision rehabilitation for people with central vision loss
This trial will test whether five weekly sessions of binocular multimodal feedback training can improve eye movement control in people with bilateral central vision loss from macular degeneration.
-
Tiespectus (MK-8748) versus aflibercept to treat neovascular (wet) age-related macular degeneration
The study will see if tiespectus (MK-8748) works as well as aflibercept for people with newly diagnosed neovascular (wet) age-related macular degeneration.
-
Comparing tiespectus (MK-8748) with aflibercept for wet age-related macular degeneration
This study will test whether tiespectus (MK-8748) works as well as aflibercept for people with newly diagnosed neovascular (wet) age-related macular degeneration.
-
See If Faricimab Helps Neovascular Age-related Macular Degeneration
This study tests whether Faricimab injections every month for 4 months can help adults aged 50 and older with active neovascular AMD in at least one eye.
-
Natural history of inherited retinal diseases
This project will test whether color vision problems relate to retinal structure and visual function in people with inherited retinal dystrophies and in people without retinal disease.
-
Assessing a vision test for patients with macular degeneration and Stargardt disease
This study is testing a new vision test to see how well it works for people with macular degeneration and Stargardt disease compared to standard vision tests.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.